Overall, in addition to controlling HCT and improving splenomegaly and symptoms, ruxolitinib provided durable and comprehensive haematological control in the RESPONSE study. Although the study was not powered to assess thromboembolic events, the lower rate observed in the ruxolitinib versus BAT arms (1·8 vs. 8·2 per 100 patient‐years of exposure) is consistent with the effects of ruxolitinib on HCT and WBC counts, which have been shown to be risk factors. Consistent comprehensive haematological control could therefore be associated with improving long‐term outcomes; however, further research is warranted.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide / Harrison C.N.; Griesshammer M.; Miller C.; Masszi T.; Passamonti F.; Zachee P.; Durrant S.; Pane F.; Guglielmelli P.; Verstovsek S.; Jones M.M.; Hunter D.S.; Sun W.; Li J.; Khan M.; Habr D.; Kiladjian J.-J.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - ELETTRONICO. - 182:(2018), pp. 279-284. [10.1111/bjh.14764]

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

Guglielmelli P.;
2018

Abstract

Overall, in addition to controlling HCT and improving splenomegaly and symptoms, ruxolitinib provided durable and comprehensive haematological control in the RESPONSE study. Although the study was not powered to assess thromboembolic events, the lower rate observed in the ruxolitinib versus BAT arms (1·8 vs. 8·2 per 100 patient‐years of exposure) is consistent with the effects of ruxolitinib on HCT and WBC counts, which have been shown to be risk factors. Consistent comprehensive haematological control could therefore be associated with improving long‐term outcomes; however, further research is warranted.
2018
182
279
284
Goal 3: Good health and well-being for people
Harrison C.N.; Griesshammer M.; Miller C.; Masszi T.; Passamonti F.; Zachee P.; Durrant S.; Pane F.; Guglielmelli P.; Verstovsek S.; Jones M.M.; Hunte...espandi
File in questo prodotto:
File Dimensione Formato  
Harrison_et_al-2018-British_Journal_of_Haematology.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 429.85 kB
Formato Adobe PDF
429.85 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1173044
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact